The Street’s view on Castle Biosciences has shifted, with the consensus analyst price target moving from about US$46.00 to ...
Beginning with Slide three, we reported a GAAP net loss attributable to StepStone Group Incorporated of $123 million or $1.55 per share. As a reminder, GAAP accounting requires us to factor the change ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results